The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis

Autoimmunity Reviews

Volumn 14, Issue 8, 2015, Pages 651-658

  Katz Agranov, Nurit ^a   Khattri, Saakshi ^b   Zandman Goddard, Gisele ^a,c  

^a Wolfson Medical Center   (Israel)

^b ROCKEFELLER UNIVERSITY   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adult Still's disease; IVIG; Rheumatoid arthritis; Rhupus syndrome; Severe infections; Vasculitis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOGLOBULINS, INTRAVENOUS;

ADULT ONSET STILL DISEASE; FELTY SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; THROMBOEMBOLISM; ARTHRITIS, RHEUMATOID; COMPLICATION; FEMALE; HUMANS; IMMUNOLOGY; INFLAMMATION; NEOPLASMS; PREGNANCY COMPLICATIONS;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84930753986     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.04.003     Document Type: Review

References (121)

1. Kivity S., Katz U., Daniel N., Nussinovitch U., Papageorgiou N., Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol 2010, 38:201-269.
2. Pyne D., Ehrenstein M., Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 2002, 41:367-374.
3. Zandman-Goddard G., Shoenfeld Y. Intravenous immunoglobulin-customized therapy. Autoimmunity: from bench to bedside 2013, [Chapter 42]. J.M. Anaya JM, Y. Shoenfeld, A. Rojas-Villarraga, R.A. Levy, R. Cervera (Eds.).
4. Katz U., Zandman-Goddard G. Update on intravenous immunoglobulins (IVIG) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des 2011, 17:3166-3175.
5. Kanik K.S., Yarboro C.H., Naparstek Y., Plotz P.H., Wilder R.L. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum 1996, 39:1027-1029.
6. Benoist C., Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?. Arthritis Res 2000, 2:90-94.
7. Pap T., Muller-Ladner U., Gay R.E., Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000, 2:361-367.
8. Gay S., Gay R.E., Koopman W.J. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?. Ann Rheum Dis 1993, 52(Suppl. 1):S39-S47.
9. Meinecke I., Rutkauskaite E., Gay S., Pap T. The role of synovial fibroblasts in mediating joint destruction in rheumatoid arthritis. Curr Pharm Des 2005, 11:563-568.
10. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010, 233:233-255.
11. Li H., Wan A. Apoptosis of rheumatoid arthritis fibroblast-like synoviocytes: possible roles of nitric oxide and the thioredoxin 1. Mediators Inflamm 2013, 2013:953462.
12. Yan D., Davis F.J., Sharrocks A.D., Im H.J. Emerging roles of SUMO modification in arthritis. Gene 2010, 466:1-15.
13. Meinecke I., Cinski A., Baier A., Peters M.A., Dankbar B., Wille A., et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci U S A 2007, 104:5073-5078.
14. Rutter A., Luger T.A. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol Jun 2001, 44:1010-1024.
15. Hooper J.A. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin N Am 2008, 28:765-778.
16. Danieli M.G., Gelardi C., Pedini V., Moretti R., Gabrielli A., Logullo F. Subcutaneous IgG in immune-mediated diseases: proposed mechanisms of action and literature review. Autoimmun Rev 2014, 13:1182-1188.
17. Sherer Y., Kuechler S., Jose Scali J., Rovensky J., Levy Y., Zandman-Goddard G. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008, 10:55-57.
18. Zandman-Goddard G., Krauthammer A., Levy Y., Langevitz P., Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:247-255.
19. Muscat C., Bertotto A., Ercolani R., Bistoni O., Agea E., Cesarotti M., et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 1995, 54:382-385.
20. Zandman-Goddard G., Krauthammer A., Shoenfeld Y. The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol 2007, 3:773-780.
21. Knezevic-Maramica I., Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 2003, 43:1460-1480.
22. Tumiati B., Casoli P., Veneziani M., Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992, 35:1126-1133.
23. Maksymowych W.P., Avina-Zubieta A., Luong M., Russell A.S. High dose intravenous immunoglobulin (IVIG) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol 1996, 14:657-660.
24. Silverman E.D., Laxer R.M., Greenwald M., Gelfand E., Shore A., Stein L.D., et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990, 33:1015-1022.
25. Uziel Y., Laxer R.M., Schneider R., Silverman E.D. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol 1996, 23:919-924.
26. Prieur A.M., Adleff A., Debre M., Boulate P., Griscelli C. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 1990, 8:603-608.
27. Silverman E.D., Cawkwell G.D., Lovell D.J., Laxer R.M., Lehman T.J., Passo M.H., et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994, 21:2353-2358.
28. Giannini E.H., Lovell D.J., Silverman E.D., Sundel R.P., Tague B.L., Ruperto N. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1996, 23:910-918.
29. Kim H.A., Sung J.M., Suh C.H. Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol Int 2012, 32:1291-1298.
30. Vignes S., Wechsler B., Amoura Z., Papo T., Frances C., Huong D.L., et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998, 16:295-298.
31. Permal S., Wechsler B., Cabane J., Perrot S., Blum L., Imbert J.C. Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 1995, 16:250-254.
32. Balint G.Z., Balint P.V. Felty's syndrome. Best Pract Res Clin Rheumatol 2004, 18:631-645.
33. Lekharaju V., Chattopadhyay C. Efficacy of rituximab in Felty's syndrome. Ann Rheum Dis 2008, 67:1352.
34. Chandra P.A., Margulis Y., Schiff C. Rituximab is useful in the treatment of Felty's syndrome. Am J Ther 2008, 15:321-322.
35. Mahévas M., Audia S., De Lastours V., Michel M., Bonotte B., Godeau B. Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine. Haematologica 2007, 92:e78-e79.
36. Ahern M., Harkness J., Maddison P., Forskitt S. High-dose immunoglobulin in Felty's syndrome. Ann Rheum Dis 1983, 42:476-477.
37. Breedveld F.C., Brand A., van Aken W.G. High dose intravenous gamma globulin for Felty's syndrome. J Rheumatol 1985, 12:700-702.
38. Hellmich B., Csernok E., Schatz H., Gross W.L., Schnabel A. Antibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002, 46:2384-2391.
39. Bevans M., Nadell J., Demartini F., Ragan C. The systemic lesion of malignant rheumatoid arthritis. Am J Med 1954, 16:298-304.
40. Hale L.P., Haynes B.F. Pathology of rheumatoid arthritis and associated disorders. Arthritis and allied conditions 1997, 993-1016. Williams & Wilkins, Philadelphia. W.J. Koopman (Ed.).
41. Maeda H., Furonaka O., Matsushima K., et al. Successful treatment of "malignant rheumatoid arthritis" in Japan with pooled intravenous immunoglobulin. Rheumatology (Oxford) 2001, 40:955-956.
42. Levy Y., Uziel Y., Zandman-Goddard G., Amital H., Sherer Y., Langevitz P., et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003, 62:1221-1223.
43. Nagashima M., Matsushima M., Matsuoka H. High dose gammaglobulin therapy for Kawasaki disease. J Pediatr 1987, 110:710-712.
44. Kusuda A., Migita K., Tsuboi M., Degawa M., Matsuoka N., Tominaga M., et al. Successful treatment of adult onset Henoch-Schönlein purpura nephritis with high-dose immunoglobulins. Intern Med 1999, 38:376-379.
45. Boman S., Ballen J.L., Seggev J.S. Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 1995, 238:375-377.
46. Jayne D.R., Lockwood C.M. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996, 35:1150-1153.
47. Levy Y., George J., Fabbrizzi F., Rotman P., Paz Y., Shoenfeld Y. Marked improvement of Churg-Strauss vasculitis with intravenous immunoglobulin. South Med J 1999, 92:412-414.
48. Guidelli G.M., Tenti S., Pascarelli N.A., Galeazzi M., Fioravanti A. Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. Autoimmun Rev 2015, 10.1016/j.autrev.2015.03.005.
49. Ballanti E., Di Muzio G., Novelli L., Perricone C., Perricone R. Churg-Strauss syndrome with neurologic manifestations: report of a case successfully treated with intravenous immunoglobulins. Isr Med Assoc J 2012, 14:583-585.
50. Jayne D.R.W., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000, 93:433-439.
51. Richter C., Schnabel A., Csernok E., De-Groot K., Reinhold-Keller E., Gross W.L. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high dose intravenous immunoglobulin. Clin Exp Immunol 1995, 101:2-7.
52. Panush R.S., Edwards N.L., Longley S., Webster E. 'Rhupus' syndrome. Arch Intern Med 1988, 148:1633-1636.
53. Tani C., D'Aniello D., Delle Sedie A., Carli L., Cagnoni M., Possemato N., et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 2013, 12:537-541.
54. Fernández A., Quintana G., Rondón F., Restrepo J.F., Sánchez A., Antonio Iglesias A., et al. Lupus arthropathy: a case series of patients with rhupus. Clin Rheumatol 2006, 25:164-167.
55. Eriksson C., Engstrand S., Sundqvist K.G., Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005, 64:403-407.
56. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
57. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
58. Andrade-Ortega L., Irazoque-Palazuelos F., Muñóz-López S., Rosales-Don Pablo V.M. Efficacy and tolerability of rituximab in patients with rhupus. Reumatol Clin 2013, 9:201-205.
59. Ikeda K., Sanayama Y., Makita S., Hosokawa J., Yamagata M., Nakagomi D., et al. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol 2013, 2013:697525.
60. Zandman-Goddard G., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005, 29:219-228.
61. Levy Y., Sherer Y., Ahmed A., Langevitz P., George J., Fabbrizzi F., et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999, 8:705-712.
62. Rauova L., Lukac J., Levy Y., Rovensky J., Shoenfeld Y. High-dose intravenous immunoglobulins for lupus nephritis-a salvage immunomodulation. Lupus 2001, 10:209-213.
63. Levy Y., Sherer Y., George J., Rovensky J., Lukac J., Rauova L., et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000, 29:321-327.
64. Wenderfer S.E., Thacker T. Intravenous immunoglobulin in the management of lupus nephritis. Autoimmune Dis 2012, 2012:589359.
65. Orbach H., Tishler M., Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004, 34:593-601.
66. Zandman-Goddard G., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005, 29:219-228.
67. Sherer Y., Levy Y., Langevitz P., Lorber M., Fabrizzi F., Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999, 18:170-173.
68. Zandman-Goddard G., Blank M., Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 2009, 18:884-888.
69. Milstone A.M., Meyers K., Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 2005, 24:394-397.
70. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011, 65:e195-e213.
71. Micheloud D., Calderon M., Caparrros M., D'Cruz D.P. Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 2007, 66:986-987.
72. Sherer Y., Levy Y., Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999, 18:238-240.
73. Zandman-Goddard G., Shoenfeld Y. Infections and SLE. Autoimmunity 2005, 38:473-485.
74. Verstappen S.M., King Y., Watson K.D., Symmons D.P., Hyrich K.L., BSRBR Control Centre Consortium, BSR Biologics Register Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:823-826.
75. Viktil K.K., Engeland A., Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012, 41:196-201.
76. Roux C.H., Brocq O., Breuil V., Albert C., Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007, 46:695-698.
77. Klink D.T., van Elburg R.M., Schreurs M.W., van Well G.T. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008, 51:1-6.
78. Chakravarty E.F., Murray E.R., Kelman A., Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011, 117:1499-1506.
79. De Carolis C., Perricone C., Perricone R. NK cells, autoantibodies, and immunologic infertility: a complex interplay. Clin Rev Allergy Immunol 2010, 39:166-175.
80. Perricone R., Di Muzio G., Perricone C., Giacomelli R., De Nardo D., Fontana L., et al. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am J Reprod Immunol 2006, 55:232-239.
81. Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 2010, 49:1040-1048.
82. Perricone R., De Carolis C., Kroegler B., Greco E., Giacomelli R., Cipriani P., et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford) 2008, 47:646-651.
83. Triolo G., Ferrante A., Accardo-Palumbo A., Ciccia F., Cadelo M., Castelli A., et al. IVIG in APS pregnancy. Lupus 2004, 13:731-735.
84. Dendrinos S., Sakkas E., Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009, 104:223-225.
85. Pisoni C.N., Brucato A., Ruffatti A., Espinosa G., Cervera R., Belmonte-Serrano M., et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62:1147-1152.
86. Stephenson M.D., Kutteh W.H., Purkiss S., Librach C., Schultz P., Houlihan E., et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010, 25:2203-2209.
87. Ruffati A., Marson P., Svaluto-Moreolo G., Marozio L., Tibaldi M., Favaro M., et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev 2013, 12:768-773.
88. Sipak-Szmigiel O., Ronin-Walknowska E., Miklaszwicz A. Application of intravenous immunoglobulin therapy (IVIG) in pregnant patients with recurrent spontaneous abortions. Ginekol Pol 2003, 74:350-355.
89. Christiansen O.B., Pedersen B., Rosgaard A., Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002, 17:809-816.
90. Coulam C.B., Krysa L., Stern J.J., Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995, 34:333-337.
91. Carp H.J., Toder V., Gazit E., Ahiron R., Torchinski A., Mashiach S., et al. Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. Am J Reprod Immunol 2001, 46:268-273.
92. Carp H.J., Ahiron R., Mashiach S., Shoenfeld Y., Gazit E.Toder V. Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol 1996, 35:360-362.
93. Clark A.L. Clinical uses of intravenous immunoglobulin in pregnancy. Clin Obstet Gynecol 1999, 42:368-380.
94. Barbhaiya M., Bermas B.L. Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clin Immunol 2013, 149:225-235.
95. Höckel M., Kaufmann R. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application-a case report. J Perinat Med 1986, 14:205-208.
96. Palmeira P., Costa-Carvalho B.T., Arslanian C., et al. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol 2009, 20:528-535.
97. Werdan K., Pilz G., Bujdoso O., Fraunberger P., Neeser G., Schmieder R.E., et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007, 35:2693-2701.
98. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013, 9:CD001090.
99. Malaguarnera M., Guccione N., Musumeci S., Brogna A., Motta M., Di Fazio I. Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C. BioDrugs 2004, 18:63-70.
100. Pildal J., Gøtzsche P.C. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004, 39:38-56.
101. Kreymann K.G., de Heer G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007, 35:2677-2685.
102. Laupland K.B., Kirkpatrick A.W., Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007, 35:2686-2692.
103. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
104. Ferrara G., Zumla A., Maeurer M. Intravenous immunoglobulin (IVIG) for refractory and difficult-to-treat infections. Am J Med 2012, 125:103-106.
105. Nowak-Wegrzyn A., Lederman H.M. Supply, use, and abuse of intravenous immunoglobulin. Curr Opin Pediatr 1999, 11:533-539.
106. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
107. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011, 127:315-323.
108. Furst D.E., Keystone E.C., Braun J., Breedveld F.C., Burmester G.R., De Benedetti F., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2012, 71:i2-i45.
109. Elandt K., Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011, 13:223.
110. Franklin J., Lunt M., Bunn D., Symmons D., Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006, 65:617-622.
111. Silman A.J., Petrie J., Hazleman B., Evans S.J. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20year follow up study. Ann Rheum Dis 1988, 47:988.
112. Wolfe F., Fries J.F. Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:2694-2695.
113. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
114. Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439.
115. Bernatsky S., Clarke A.E., Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008, 168:378-381.
116. Loughran T.P. Clonal diseases of large granular lymphocytes. Blood 1993, 82:1-14.
117. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701.
118. Katz U., Achiron A., Sherer Y., Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007, 6:257-259.
119. Sapir T., Blank M., Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 2005, 1051:743-778.
120. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin, adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:173-183.
121. Mark S.M. Comparison of intravenous immunoglobulin formulations: product, formulary, and cost considerations. Hosp Pharm 2011, 46:668-676.